The synergistic antitumour activity and pharmacodynamics of BBI-2779 was evaluated in combination with the pan-FGFR tyrosine kinase inhibitor infigratinib in the FGFR2-amplified ecDNA+ gastric cancer SNU16 xenograft tumour model. Here, FGFR2 is linked to neoplasm.